Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Congress 2019

Mini Oral session - Developmental and precision medicine

Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)

Date

22 Nov 2019

Session

Mini Oral session - Developmental and precision medicine

Topics

Cytotoxic Therapy

Tumour Site

Thyroid Cancer;  Non-Small Cell Lung Cancer

Presenters

Dae Ho Lee

Citation

Annals of Oncology (2019) 30 (suppl_9): ix122-ix130. 10.1093/annonc/mdz431

Authors

D.H. Lee1, V. Subbiah2, J.F. Gainor3, M.H. Taylor4, V.W. Zhu5, R.C. Doebele6, G. Lopes7, C. Baik8, E. Garralda9, S.M. Gadgeel10, D. Kim11, C.D. Turner12, M. Palmer13, S. Miller13, G. Curigliano14

Author affiliations

  • 1 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 2 Department Of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 3 Department Of Medicine, Massachusetts General Hospital, 02114 - Boston/US
  • 4 Knight Cancer Institute, Oregon Health & Science University, 97210 - Portland/US
  • 5 Department Of Medicine, UC Irvine, Orange/US
  • 6 Division Of Medical Oncology, University of Colorado, 80045 - Aurora/US
  • 7 Sylvester Comprehensive Cancer Center, University of Miami, 33136 - Miami/US
  • 8 Seattle Cancer Care Alliance Inpatient Unit, University of Washington, Seattle/US
  • 9 Cellex Center, Vall d`Hebron Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 10 Department Of Internal Medicine, University of Michigan, 48109-5942 - Ann Arbor/US
  • 11 Departments Of Hemato Oncology, Medical Oncology Center, Personalized Cancer Medicine Center Hemato-oncology, Seoul National University Hospital, 110-744 - Seoul/KR
  • 12 Clinical Development, Blueprint Medicines Corporation, Cambridge/US
  • 13 Translational Medicine, Blueprint Medicines Corporation, 02139 - Cambridge/US
  • 14 Early Drug Development for Innovative Therapies Division, University Of Milano, Istituto Europeo di Oncologia, 20141 - Milan/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.